RegisterLogin

Remodelin

CAT: 0804-HY-16706-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-16706-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model[1][2][3][4].
CAS Number
[949912-58-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Acetyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Remodelin.html
Purity
99.84
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
N#CC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1
Molecular Formula
C15H14N4S
Molecular Weight
282.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Larrieu D, et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014 May 2;344 (6183) :527-32.|[2]Ma N, et.al. Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication. Int J Mol Sci. 2022 Jun 12;23 (12) :6573. |[3]Balmus G, et.al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun. 2018 Apr 27;9 (1) :1700. |[4]Zhang X, et.al. N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition. Oxid Med Cell Longev. 2019 Jul 1;2019:7561879.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Adv Sci (Weinh) . 2025 Dec;12 (46) :e04245.|bioRxiv. 2023 Feb 11.|Cell Death Dis. 2023 Nov 1;14 (11) :712.|Cell Rep. 2023 Jul 17;42 (7) :112810.|J Agric Food Chem. 2022 Jan 12;70 (1) :403-414.|J Hazard Mater. 2025 Oct 19:499:140193.|J Virol. 2024 Jan 23;98 (1) :e0135023.|Life Sci. 2023 Oct 1:330:121948.|Acta Pharmacol Sin. 2023 Oct;44 (10) :2125-2138.|bioRxiv. 2025 Sep 1:2025.09.01.673489.|Epigenetics. 2024 Dec;19 (1) :2417158.|Heliyon. 2023 Jun 8;9 (6) :e17103.|iScience. 2025 Jun 9;28 (7) :112860.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Oncogene. 2021 Apr;40 (15) :2711-2724.|SSRN. 2025 Jul 28.

Related Products

CatalogName

Alternative Products

CatalogName
MBS385672-01Remodelin
M12787-01Remodelin Fluor
464608-01Remodelin Hydrobromide
MBS130839-01Remodelin HBr
A21985-25Remodelin 25mg
A21985-100Remodelin 100mg

Popular Products